EU/3/10/747

  • Email
  • Help

Orphan designation

On 9 June 2010, orphan designation (EU/3/10/747) was granted by the European Commission to Aveo Pharma Ltd, United Kingdom, for N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate (also known as tivozanib) for the treatment of renal-cell carcinoma.

The sponsorship was transferred to Astellas Pharma Europe B.V., the Netherlands in March 2012.

For a list of the administrative updates to this public summary of opinion, please refer to the PDF document below.

What is renal-cell carcinoma?

Renal-cell carcinoma is a type of kidney cancer that originates in the cells lining the kidney tubules. These are small tubes that filter waste products out from the blood and make urine. Signs of renal-cell carcinoma are difficult to detect in the early stages of the disease, and about half of the patients are diagnosed when the cancer has spread around the kidney or to other parts of the body.

Renal-cell carcinoma is more common in men than in women. It is a life-threatening disease that is associated with poor long-term survival.

What is the estimated number of patients affected by the condition?

At the time of designation, renal-cell carcinoma affected less than 4.2 in 10,000 people in the European Union (EU). This is equivalent to a total of fewer than 213,000 people*, and is below the threshold for orphan designation, which is 5 people in 10,000. This is based on the information provided by the sponsor and the knowledge of the Committee for Orphan Medicinal Products (COMP).


*Disclaimer: For the purpose of the designation, the number of patients affected by the condition is estimated and assessed on the basis of data from the European Union (EU 27), Norway, Iceland and Liechtenstein. At the time of designation, this represented a population of 506,300,000 (Eurostat 2010).

What treatments are available?

At the time of designation, several medicines were authorised in the EU for the treatment of renal-cell carcinoma. The main treatment was surgery, which was combined with radiotherapy (treatment with radiations) and chemotherapy (medicines to treat cancer) when the cancer had spread outside of the kidneys.

The sponsor has provided sufficient information to show that this medicine might be of significant benefit for patients with renal-cell carcinoma because it might improve the treatment of patients with this condition, and early studies in experimental models show that it might be more potent and more specific than existing treatments with similar mode of action. This assumption will need to be confirmed at the time of marketing authorisation, in order to maintain the orphan status.

How is this medicine expected to work?

This medicine is expected to work by blocking some enzymes called ‘tyrosine kinases’ that are found in ‘vascular endothelial growth factor’ (VEGF) receptors. These receptors, which can be found on the surface of cancer cells, are involved in the development of new blood vessels that supply the tumours. By blocking VEGF receptors, this medicine is expected to slow down the growth of cancer cells by reducing their blood supply.

What is the stage of development of this medicine?

The effects of N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate have been evaluated in experimental models.

At the time of submission of the application for orphan designation, clinical trials with this medicine in patients with renal-cell carcinoma were ongoing.

At the time of submission, this medicine was not authorised anywhere in the EU for renal-cell carcinoma or designated as an orphan medicinal product elsewhere for this condition.

In accordance with Regulation (EC) No 141/2000 of 16 December 1999, the COMP adopted a positive opinion on 3 March 2010 recommending the granting of this designation.

Opinions on orphan medicinal product designations are based on the following three criteria:
  • the seriousness of the condition;
  • the existence of alternative methods of diagnosis, prevention or treatment;
  • either the rarity of the condition (affecting not more than 5 in 10,000 people in the EU) or insufficient returns on investment.

Designated orphan medicinal products are products that are still under investigation and are considered for orphan designation on the basis of potential activity. An orphan designation is not a marketing authorisation. As a consequence, demonstration of quality, safety and efficacy is necessary before a product can be granted a marketing authorisation.

Key facts

Product details for <p>N-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate</p>
Active substanceN-{2-Chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) urea hydrochloride monohydrate
Medicine Name
Disease/conditionTreatment of renal-cell carcinoma
Date of decision09/06/2010
OutcomePositive
Orphan decision numberEU/3/10/747

Review of designation

Sponsor’s contact details

Astellas Pharma Europe BV
Sylviusweg 62
2333 BE Leiden
The Netherlands
Tel. +31 71 5455 745
Fax +31 71 545 5501
E-mail: contact@astellas.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.